New paradigms in the treatment of wet AMD: The impact of anti-VEGF therapy

Eye (Basingstoke)

Volumn 23, Issue 1, 2009, Pages S1-S7

  Menon, G ^a   Walters, G ^b  

^a FRIMLEY PARK HOSPITAL   (United Kingdom)

^b Consultant Ophthalmologist ^*  (United Kingdom)

Author keywords

Age related macular degeneration; Anti VEGF therapy; Commissioning; Cost effectiveness; Pegaptanib; Photodynamic therapy

Indexed keywords

PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

BLINDNESS; DISEASE COURSE; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAINTENANCE THERAPY; MEDICAL SPECIALIST; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TREATMENT DURATION; UNITED KINGDOM; VISUAL IMPAIRMENT;

EID: 62549126898     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.13     Document Type: Article

References (18)

1. Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R et al. The natural history and prognosis of neovascular age-related macular degeneration. Ophthalmology 2008; 115: 116–126.
2. Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G, Michels SM. Effects of verteporfin therapy on central visual field function. Ophthalmology 2004; 111: 931–939.
3. Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999–March 2000. Eye 2008; 22: 905–911.
4. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640–1642.
5. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008; 358: 2606–2617.
6. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006; 58: 353–363.
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
8. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al, ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444.
9. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al, PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239–248.
10. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–2816.
11. TA68 Macular degeneration (age related) Fphotodynamic therapy: Guidance. 2003. Available at http://www.nice.org.uk/nicemedia/pdf/68_PDTGuidance.pdf (accessed on 1 February 2009).
12. RCOphth commissioning contemporary AMD services: a guide for commissioners and clinicians. 2007. Available at http://www.rcophth.ac.uk/docs/publications/published-guidelines/CommissionContempAMDServicesV3Final.pdf (accessed on 1 February 2009).
13. Macular degeneration (age-related)-ranibizumab and pegaptanib: Final appraisal determination. 2008. Available at http://www.nice.org.uk/nicemedia/pdf/TA155guidance.pdf (accessed on 1 February 2009).
14. Ranibizumab 10 mg/ml solution for intravitreal injection (No. 381/07). Available at http://www.scottishmedicines.org.uk/smc/files/ranibizumab_10mgmlsolution_intravitrealinjection_Lucentis_38107.pdf (accessed on 1 February 2009).
15. Pegaptanib 0.3mg solution for intravitreal injection (No. 290/06). Available at http://www.scottishmedicines.org.uk/smc/files/pegaptanib_Macugen_290_06.pdf (accessed on 1 February 2009).
16. The Royal College of Ophthalmologists. Ranibizumab: the clinician’s guide to commencing, continuing and discontinuing treatment. Available at http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_June_2008.pdf (accessed on 1 February 2009).
17. Lucentis: summary of product characteristics. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-PI-en.pdf (accessed on 1 February 2009).
18. Macugen: summary of product characteristics. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/macugen/H-620-PI-en.pdf (accessed on 1 August 2008).